Bronchial asthma, hypertension and COVID-19: A case report

Bronchial asthma is mentioned as a factor that worsens the condition of COVID-19 and vice versa. Hypertension is also comorbid that aggravates SARS-COV-2 infection. The aim of this case report is to present that bronchial asthma and hypertension may not worsen COVID-19 patients. We report a woman, 53 years old, positive swab RT-PCR result, comorbid uncontrolled hypertension, and partially controlled asthma. During treatment, there is anxiety, but bronchial asthma and hypertension can be controlled. Some of the drugs administered include antiviral favipiravir, systemic steroids, anti-IL-6 (tocilizumab), antihypertensives, bronchodilator inhalers, anti-anxiety, plasma convalescence, anticoagulants, vitamins, and other anti-oxidants. Multidisciplinary management accelerates the improvement of the patient’s condition. Good bronchial asthma and hypertension management will control the patient’s condition and will not cause worsening during treatment due to COVID-19. Bronchial asthma and hypertension may not worsen COVID-19 if the therapy of COVID-19 and all comorbid can be controlled.